• Hong-Jie Chi, Mu-Lei Chen, Xin-Chun Yang, Xiang-Min Lin, Hao Sun, Wen-Shu Zhao, Dan Qi, Jia-Lu Dong, and Jun Cai.
• Department of Cardiology, Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
• Curr Drug Targets. 2017 Jan 1; 18 (15): 1712-1721.

BackgroundExperimental studies of acute myocardial infarction have revealed that up to half of the final infarct size may be due to reperfusion injury rather than the initial ischemic incident. Research over the past three decades has deepened our understanding of the molecular mechanisms underlying ischemic reperfusion injury and several therapeutic strategies to decrease the incidence and severity of reperfusion injury have been explored.ObjectiveTo discuss the promising therapies and future perspectives on methods to attenuate myocardial reperfusion injury.ResultsExisting therapies that address reperfusion can be divided into two major groups comprising nonpharmacological and pharmacological interventions. Myriad pharmacological and nonpharmacological approaches to reduce lethal reperfusion injury have been employed. Although many initial clinical studies were negative, more recent proof-of-concept clinical trials are promising. To date, the most encouraging results are with ischemic postconditioning, remote ischemic preconditioning, ANP, adenosine, cyclosporine and exenatide.ConclusionStudies demonstrate that nonpharmacological and pharmacological conditioning can be used together as part of a multifaceted approach to improve clinical outcomes in patients with ischemic heart disease.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

28 keywords...

hide…